Patents Represented by Attorney Jeffrey A. Hagenah

Find this attorney in the Justia Lawyer Directory

  • Crystalline forms of an 8-azabicyclo[3.2.1]octane compound
    Patent number: 8247555
    Abstract: The invention provides a crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline salt forms.
    Type: Grant
    Filed: April 6, 2011
    Date of Patent: August 21, 2012
    Assignee: Theravance, Inc.
    Inventors: Sean M. Dalziel, Leticia M. Preza, Miroslav Rapta, Pierre-Jean Colson
  • Compounds having BETA2 adrenergic receptor agonist and muscarinic receptor antagonist activity
    Patent number: 8247564
    Abstract: The invention is directed to compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7a, R7b, W, G1, G2, a, b, c, d and m are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: October 13, 2010
    Date of Patent: August 21, 2012
    Assignee: Theravance, Inc.
    Inventors: Mathai Mammen, Sarah Dunham
  • 3-(phenoxyphenylmethyl)pyrrolidine compounds
    Patent number: 8242164
    Abstract: In one aspect, the invention relates to compounds of formula I: where a and R1-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: January 4, 2011
    Date of Patent: August 14, 2012
    Assignee: Theravance, Inc.
    Inventors: Eric L. Stangeland, Priscilla Van Dyke, Timothy J. Church, Lori Jean Patterson, Daisuke Roland Saito
  • Biphenyl derivatives
    Patent number: 8242135
    Abstract: This invention provides biphenyl derivatives of formula I: wherein R1, R2, R3, R4, R5, R6, R7, W, a, b and c are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The biphenyl derivatives of this invention possess both ?2 adrenergic receptor agonist and muscarinic receptor antagonist activity and therefore, such biphenyl derivatives are useful for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: August 14, 2012
    Assignee: Theravance, Inc.
    Inventors: Mathai Mammen, Eric Stangeland
  • Amidine-containing compounds useful as muscarinic receptor antagonists
    Patent number: 8242138
    Abstract: The invention relates to compounds of formula I: or a pharmaceutically acceptable salt thereof, where R1-3, R5, R7, a, b, Q, X, X?, X?, Y, Z, and Ar are as defined in the specification. These compounds are muscarinic receptor antagonists. The invention also relates to pharmaceutical compositions containing such compounds, processes for preparing such compounds and methods of using such compounds to, for example, treat pulmonary disorders such as chronic obstructive pulmonary disease and asthma.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: August 14, 2012
    Assignee: Theravance, Inc.
    Inventors: YuHua Ji, Craig Husfeld, Rick Lee, YongQi Mu
  • Crystalline forms of a biphenyl compound
    Patent number: 8242137
    Abstract: The invention provides crystalline forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester, and pharmaceutically acceptable solvates thereof. The crystalline form can be a freebase, or a salt such as a diphosphate, monosulfate or dioxalate salt. The invention also provides pharmaceutical compositions comprising these crystalline compounds or prepared using these compounds; processes and intermediates for preparing the crystalline compounds; and methods of using these compounds to treat a pulmonary disorder.
    Type: Grant
    Filed: September 21, 2009
    Date of Patent: August 14, 2012
    Assignee: Theravance, Inc.
    Inventors: Sabine Axt, Timothy J. Church
  • Dual-acting antihypertensive agents
    Patent number: 8236839
    Abstract: The invention relates to compounds having the formula: wherein: Ar, r, R3, Z, X, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: August 7, 2012
    Assignee: Theravance, Inc.
    Inventors: Seok-Ki Choi, Paul R. Fatheree, Roland Gendron, Ryan Hudson, Robert Murray McKinnell, Vivek Sasikumar
  • Dual-acting antihypertensive agents
    Patent number: 8236846
    Abstract: The invention is directed to compounds having the formula: wherein: Ar, r, Y, Z, Q, W, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: July 26, 2011
    Date of Patent: August 7, 2012
    Assignee: Theravance, Inc.
    Inventors: Paul Allegretti, Seok-Ki Choi, Roland Gendron, Paul Fatheree, Keith Jendza, Robert Murray McKinnell, Darren McMurtrie, Brooke Olson
  • Methods for detecting sulfhydryl-containing compounds in a biological test sample
    Patent number: 8232306
    Abstract: The invention relates to methods for detecting the presence of a compound of formula I in a biological test sample: where R2, R3, and R4 are as defined in the specification; or a salt thereof.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: July 31, 2012
    Assignee: Theravance, Inc.
    Inventors: Yuqin Dai, Donavon McConn, Huiyu Zhou
  • Dual-acting antihypertensive agents
    Patent number: 8227497
    Abstract: The invention relates to compounds having the formula: wherein: Q, W, Y, Z, r, and Ar are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: June 22, 2011
    Date of Patent: July 24, 2012
    Assignee: Theravance, Inc.
    Inventors: Paul Allegretti, Seok-Ki Choi, Roland Gendron, Paul R. Fatheree, Robert Murray McKinnell
  • Biphenyl compounds useful as muscarinic receptor antagonists
    Patent number: 8211915
    Abstract: This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, s, t, Ar1, R1, R2, R3, R4, R6, R7, R8, and W are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
    Type: Grant
    Filed: September 13, 2010
    Date of Patent: July 3, 2012
    Assignee: Theravance, Inc.
    Inventors: Mathai Mammen, YuHua Ji, YongQi Mu
  • Dual-acting benzoimidazole antihypertensive agents
    Patent number: 8212052
    Abstract: The invention relates to compounds having the formula: wherein Ar, r, n, X, R2, R2?, R3, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and a process and intermediates for preparing such compounds.
    Type: Grant
    Filed: December 8, 2008
    Date of Patent: July 3, 2012
    Assignee: Theravance, Inc.
    Inventors: Seok-Ki Choi, Paul R. Fatheree, Robert Murray McKinnell, Brooke Olson
  • Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
    Patent number: 8211894
    Abstract: The invention provides heteroarylene substituted 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, A, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: February 11, 2010
    Date of Patent: July 3, 2012
    Assignee: Theravance, Inc.
    Inventors: Daniel D. Long, Lan Jiang, Daisuke Roland Saito, Priscilla Van Dyke
  • Quaternary ammonium compounds useful as muscarinic receptor antagonists
    Patent number: 8202891
    Abstract: The invention provides compounds of the formula: in salt or zwitterionic form or a pharmaceutically acceptable salt thereof, wherein R1-6, a, Z and Q are as defined in the specification. These compounds are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes for preparing such compounds and methods of using such compounds to, for example, treat pulmonary disorders such as chronic obstructive pulmonary disease and asthma.
    Type: Grant
    Filed: April 23, 2008
    Date of Patent: June 19, 2012
    Assignee: Theravance, Inc.
    Inventors: Craig Husfeld, YuHua Ji, Rick Lee, Li Li, YongQi Mu, Cameron Smith, Johnny Uy
  • Guanidine-containing compounds useful as muscarinic receptor antagonists
    Patent number: 8198304
    Abstract: The invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein R1-3, R5-7, a, X, Y, Y?, Y?, and Z are as defined in the specification. These compounds are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes for preparing such compounds and methods of using such compounds to, for example, treat pulmonary disorders such as chronic obstructive pulmonary disease and asthma.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: June 12, 2012
    Assignee: Theravance, Inc.
    Inventors: YuHua Ji, Craig Husfeld, YongQi Mu, Rick Lee, Li Li
  • Process for preparing biphenyl imidazole compounds
    Patent number: 8188294
    Abstract: The invention provides processes for preparing intermediates useful for preparing compounds of the formula: or a salt thereof, where R1-3 are as defined in the specification.
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: May 29, 2012
    Assignee: Theravance, Inc.
    Inventors: Weijiang Zhang, Pierre-Jean Colson
  • Biphenyl compounds useful as muscarinic receptor antagonists
    Patent number: 8173815
    Abstract: This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
    Type: Grant
    Filed: September 7, 2011
    Date of Patent: May 8, 2012
    Assignee: Theravance, Inc.
    Inventors: Mathai Mammen, YuHua Ji, YongQi Mu, Craig Husfeld, Li Li
  • Quinolinone-carboxamide compounds as 5-HTreceptor agonists
    Patent number: 8163920
    Abstract: The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: April 24, 2012
    Assignee: Theravance, Inc.
    Inventors: Daniel Marquess, Paul R. Fatheree, S. Derek Turner, Daniel D. Long, Adam A. Goldblum, Daniel Genov
  • Crystalline form of a 3-phenoxymethylpyrrolidine compound
    Patent number: 8163794
    Abstract: The invention provides a crystalline hydrochloride salt of (S)-3-[(S)-1-(4-chlorophenoxy)-2-methylpropyl]pyrrolidine. This invention also provides pharmaceutical compositions comprising the crystalline salt, processes and intermediates for preparing the crystalline salt, and methods of using the crystalline salt to treat diseases.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: April 24, 2012
    Assignee: Theravance, Inc.
    Inventors: Daisuke Roland Saito, Miroslav Rapta
  • Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
    Patent number: 8158580
    Abstract: Disclosed are pharmaceutical compositions containing a cyclodextrin and a therapeutically effective amount of a glycopeptide antibiotic or a salt thereof. Also disclosed are methods of treating a bacterial disease in a mammal by administering such pharmaceutical compositions.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: April 17, 2012
    Assignee: Theravance, Inc.
    Inventors: J. Kevin Judice, Jeng-Pyng Shaw, YongQi Mu, Michael W. Conner, John L. Pace